Zhejiang Lepu Pharmaceutical Co., Ltd., established in 2001, is located in Jiaojiang block, Taizhou chemical API Industrial Park, Zhejiang Province. The company covers an area of nearly 300 mu, Lepu (Beijing) medical device Co., Ltd (stock code 300003) is a core subsidiary of Lepu Pharmaceutical Technology Co., Ltd. and Zhejiang Lepu pharmaceutical import and Export Co., Ltd. It is mainly engaged in the R&D, production and sales of cardiovascular, anti infective, anti-tumor and nervous system drugs. Its main products include atorvastatin calcium, rosuvastatin calcium, norfloxacin and other APIs and preparations It attaches great importance to product quality and has successively passed GMP certification and registration such as China nm-pa, US FDA, EU EDQM, Japan PMDA and Korea KFDA. Many varieties occupy a leading position in the world. The company is a national high-tech enterprise, one of the first demonstration units for the transfer and transformation of national scientific and technological achievements, and a high-quality manufacturing enterprise in Zhejiang. It has built a national academician workstation, a postdoctoral workstation and a Provincial Research Institute, with strong R & D capability. It has jointly established laboratories with domestic famous universities and scientific research institutes such as Zhejiang University, Nankai University and Shanghai Institute of medical technology, and hired a group of professors and industry experts as R & D guidance, building a bridge between industrial capital and intellectual capital. In recent years, more than 40 invention patents have been authorized and more than 50 new products have been developed. Among them, the project of "key technology and industrialization of atorvastatin calcium chemical enzymatic synthesis" has won the first prize of scientific and technological progress of Zhejiang Province. Atorvastatin calcium tablets passed the quality consistency evaluation and won the bid for centralized collection. The company has extensive cooperation with many large international companies to strengthen the research and development of new drugs and provide lasting power for the medium and long-term development of the enterprise. The company's marketing network covers five continents and has established partnerships with nearly 600 customers at home and abroad in more than 70 countries and regions. Many products lead the sales in the international market, among which the sales of main varieties of atorvastatin calcium account for more than 50% of the world. Looking forward to the future, the company will focus on developing solid preparations and APIs, build a multi-functional Incubation Platform for APIs and preparations, and create a good situation of "troika" of APIs, preparations and CMO. "Ignite the brilliance of life from the heart with the power of science and technology". The company will follow the medical industry policy, increase technological innovation, accelerate transformation and upgrading, rely on the big health industry of Lepu (Beijing) medical device company, really do solid work, explore and innovate, improve the core competitiveness of the enterprise, and strive to build a green pharmaceutical enterprise with international competitiveness and popularity.